TURNING PT THER (TPTX)
(Delayed Data from NSDQ)
$32.54 USD
-1.16 (-3.44%)
Updated May 3, 2019 04:00 PM ET
After-Market: $32.56 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$32.54 USD
-1.16 (-3.44%)
Updated May 3, 2019 04:00 PM ET
After-Market: $32.56 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CSML
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CSML
Bristol-Myers (BMY) Q2 Earnings, Sales Beat on Eliquis, Opdivo
by Zacks Equity Research
Bristol-Myers (BMY) earnings and sales beat estimates in the second quarter of 2022 on the back of Eliquis and Opdivo and a lesser decline in sales of Revlimid.
Bristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?
by Zacks Equity Research
Investors will likely focus on the demand for Eliquis and Opdivo along with incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results. Operating expenses might have jumped.
Bristol Myers (BMY) Up 20.4% YTD: Will the Momentum Continue?
by Zacks Equity Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.
The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics
by Zacks Equity Research
Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.
Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More
by Zacks Equity Research
Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA
by Zacks Equity Research
Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.
What Makes Turning Point Therapeutics (TPTX) a New Buy Stock
by Zacks Equity Research
Turning Point Therapeutics (TPTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics
5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty
by Kinjel Shah
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in 2021. However, with demand trends expected to improve, USNA, RDUS, ONCT, ORGO and TPTX may prove to be good additions to one's portfolio.
Turning Point Therapeutics (TPTX) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Turning Point Therapeutics (TPTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Turning Point Therapeutics (TPTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Turning Point Therapeutics (TPTX) delivered earnings and revenue surprises of 14.58% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Q1 Earnings Due on May 12: ADPT, VIR, TPTX
by Kinjel Shah
Let us take a look at three biotech companies due to release their first-quarter financial results on May 12.
Will Turning Point Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Turning Point Therapeutics
Is Turning Point Therapeutics (TPTX) Stock a Solid Choice Right Now?
by Zacks Equity Research
Turning Point Therapeutics (TPTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK
5 Best Performing IPOs of 2019
by Manaswita Ghosh Dutta
This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.
Turning Point (TPTX) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
Turning Point (TPTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme
4 Best-Performing IPOs So Far in 2019
by Nitish Marwah
Companies that went public this year and did well in terms of price performance did so on the back of solid financials, positive cash flows and growing revenues.